Medline stock
Price history
−8.52% over the periodFull history: from $41.65 (December 19, 2025) to $38.10 (November 17, 2026), −8.52%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $38.10 |
| October 30, 2026 | $32.12 |
| September 25, 2026 | $34.70 |
| August 28, 2026 | $35.28 |
| July 31, 2026 | $39.28 |
| June 26, 2026 | $38.87 |
| May 29, 2026 | $36.56 |
| April 24, 2026 | $44.76 |
| March 27, 2026 | $41.36 |
| February 27, 2026 | $47.51 |
| January 30, 2026 | $44.20 |
| December 26, 2025 | $44.13 |
| December 19, 2025 | $41.65 |
At a glance
The company
Manufactures and distributes medical-surgical products and provides supply chain solutions for hospitals, surgery centers and healthcare facilities in the US and internationally
Latest results
Quarter to September 30, 2026 · EPS $0.44 (estimate $0.35)
TickerLandia's take on Medline
- Priced in line with similar companies: trailing 12-month P/E 40 vs 40 (+0%) in a group of 9.
- Strong point: Growth (83/100 in its group). Weak point: Profitability (13/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−25.94% from the 52-week high
Analysts · 27 analysts
Average target$44.31+17.59% vs. price
Buy 23 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Medline
Compared with similar companies: very low profitability and very high growth.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage46
How much it costs relative to what it produces.
Metric Value Position in group Price/book 2.42 34 Price/sales 0.94 7 P/E (trailing 12 months) 40.2 58 Forward P/E 26.2 60 EV/EBITDA 22.6 72 Profitabilityvery low13
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 5.0% 7 ROA 2.5% 13 Gross margin 25.1% 4 Net margin 2.3% 16 ROE 4.9% 22 Earnings stabilityaverage42
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 18 Margin variabilitycounts in reverse: lower means more earnings stability 1.9% 66 Growthvery high83
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +9.85% 75 Earnings growth (year over year) +261.98% 92 Revenue growth (year over year) +11.60% 83 Financial strengthlow36
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 2.31 12 Debt/equitycounts in reverse: lower means more financial strength 0.66 29 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.47 14 Current ratio 4.33 90 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage55
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +12.81% 78 Relative strength (6 months) +4.00% 51 Distance from 200-day average −4.15% 36 Riskhigh65
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 36.7% 67 Volatility (60 days) 50.0% 77 Beta (1 year) 0.71 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Medline is in line with similar companies
Medline's P/E (trailing 12 months): 40.2, in line with the median of a group of 9 similar companies (40.2).
Compared with 9 similar companies
| Metric | Medline | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 40.2 | Middle | |
| Forward P/E | 26.2 | Middle | |
| Operating margin | 5.0% | Low | |
| ROE | 4.9% | Middle | |
| Debt/equity | 0.66 | High |
Grey band: the middle half of the group; tick: the median; dot: Medline. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$7.69B
Latest quarter · Q2 2026
Net income
$60M
Latest quarter · Q2 2026
Quarterly net margin
0.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $42.57B
- P/E
- 40.2
- EPS
- $0.65
- Volume
- 10.65M
- Daily trading
- €364.21M
How Medline is changing
All resultsRevenue grew 9.9% a year on average over the last 3 years
Operating margin rose from 4.0% to 7.7%
Profits turn into cash: free cash flow equal to 157% of net income
Returns
Medline returns
| Period | Medline | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +8.27% | −3.17% | $1,083 |
| 6 months | +4.12% | +0.11% | $1,041 |
| Year to date | −9.29% | +8.34% | $907 |
Over the last 6 months it has done better than 30% of the stocks in the Healthcare sector.
Price only, without dividends.
The chart in detail
Medline: technical analysis
Medline shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 24.6% below its all-time closing high ($49.99, February 24, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- −4.15%
Support and resistance
Price areas where Medline has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$43.77+16.17%3 touches, last on July 7, 2026
- Resistance$42.34+12.37%2 touches, last on August 4, 2026
- Resistance$40.90+8.55%2 touches, last on March 27, 2026
- Last price$37.68
- Support$37.16−1.39%6 touches, last on October 16, 2026
- Support$35.02−7.07%3 touches, last on October 13, 2026
- Support$32.80−12.95%3 touches, last on August 20, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.71
- Volatility (60 sessions, annualised)
- 50.0%
- Largest fall in the last year
- −36.71%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Medline and its competitors
With 45,000 employees, Medline makes and distributes medical supplies for hospitals, ambulatory surgical facilities, doctors' offices and long-term care settings in the United States and abroad. Its Medline Brand segment covers three areas: operating room and perioperative products such as surgical trays, drapes, gowns and orthopedic implants; patient-care items such as wound dressings, exam gloves, incontinence products and infection control supplies; and laboratory and diagnostic equipment, including point-of-care testing and vital signs monitors.
- Headquarters
- Northfield, United States
- Employees
- 45,000
- Founded
- 1966
- Chief executive
- James Boyle
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MedlineMDLN | $42.57B | 5.0% | 40.2 | +4.12% |
| ResMedRMD | $33.5B | 34.0% | 21.8 | +17.82% |
| Becton, DickinsonBDX | $58.96B | 15.7% | 42.8 | +50.15% |
| West Pharmaceutical ServicesWST | $29.1B | 22.9% | 46.9 | +36.72% |
| SolventumSOLV | $15.07B | 5.9% | 99.6 | +15.89% |
| Baxter InternationalBAX | $13.41B | 7.6% | — | +48.90% |
Same industry or related industries, similar size. Compare Medline with its competitors · Full profile
